Further evaluation demonstrated that innate immune induction specifically by NOD1 agonists also blocked SARS-CoV2 in vitro infection without a broad activation of inflammatory signaling in myeloid cells, suggesting the use of NOD1 agonists as a putative novel antiviral strategy against SARS-CoV-2. This evidence concerns the gene NOD1 and infection.